Back to today’s briefing

Story perspectives

Novo Nordisk Board Shakeup: Leadership Renewal in November

10/23/2025

36 6 Full Breakdown

Summary

Story summary

Novo Nordisk's independent directors will resign in November, including Helge Lund, chair of Novo Nordisk.
The Novo Nordisk Foundation, controlling over 70% of voting power, seeks comprehensive leadership renewal after a dispute with the board.
Lars Rebien Sørensen, former CEO of Novo Nordisk, will return as temporary chair.
An extraordinary shareholders meeting is set for November 14 to elect new board members and shift focus to the U.S. market.

History

Historical Context

Novo Nordisk, founded in 1989 through a merger of two Danish companies, has become a leader in diabetes care and obesity treatments, significantly impacting Denmark's economy. In 2018, the company faced backlash over insulin pricing, prompting calls for reform. As of November 14, 2023, an extraordinary shareholders meeting could reshape its governance amid ongoing market pressures and leadership disputes.

1 of 2

Story summary

Novo Nordisk's independent directors will resign in November, including Helge Lund, chair of Novo Nordisk.
The Novo Nordisk Foundation, controlling over 70% of voting power, seeks comprehensive leadership renewal after a dispute with the board.
Lars Rebien Sørensen, former CEO of Novo Nordisk, will return as temporary chair.
An extraordinary shareholders meeting is set for November 14 to elect new board members and shift focus to the U.S. market.

1 / 2